Aphios Announces Presentation of Phase II/III Clinical Trial Data on Zindol® for Cancer Chemotherapy Induced Nausea

Published: May 26, 2009

WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that the results of a Phase II/III clinical trial of Zindol® for cancer chemotherapy induced nausea will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May 29 to June 02, 2009 in Orlando, FL. Zindol® is an enhanced ginger product.

Back to news